R21/Matrix-M booster maintains high efficacy against first and multiple episodes of clinical malaria
The phase 1/2b clinical trial on R21/Matrix-M malaria vaccine has recently reported the safety and efficacy of booster vaccination at 12 months. The entire report has been published in The Lancet ...
Matrix-M is Novavax’s proprietary adjuvant technology used to enhance immune response in vaccines. The company noted that this agreement, along with other recently formed partnerships, demonstrates ...
Novavax's Matrix-M adjuvant enhances immune responses and reduces antigen requirements, distinguishing itself with a non-aluminum profile. The licensing agreement involves Pfizer paying $30 million ...
(RTTNews) - Novavax, Inc. (NVAX) announced Tuesday progress on its collaboration and license agreement (CLA) with Sanofi SA (SNY) regarding Novavax's Matrix-M adjuvant. The companies have amended ...
At the J. P. Morgan Healthcare Conference 2026, Novavax’s President and CEO, John C. Jacobs, reviewed the company’s successes in 2025 and shared its growth strategy for 2026 and beyond. From a ...
GAITHERSBURG, Md., Jan. 20, 2026 /PRNewswire/ -- Novavax, Inc. has entered into a license agreement with Pfizer for use of Novavax's Matrix-M ® adjuvant. Under the terms of the agreement, Pfizer will ...
This article first appeared on GuruFocus. Novavax (NASDAQ:NVAX) got a lift early Tuesday after the vaccine maker landed a licensing deal with Pfizer that puts its Matrix-M adjuvant to work in Pfizer's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results